Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGM1812 in Healthy and Non-diabetic Overweight or Obese Chinese Participants
NCT07294235Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BGM1812 in obesity and Overweight (4 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoint: Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs). Started Dec 2025; status: completed.
02
Drugs
BGM1812
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07294235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294235.